fluprednisolone has been researched along with Complication, Postoperative in 12 studies
Fluprednisolone: A synthetic glucocorticoid with anti-inflammatory properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Difluprednate administered twice a day was at least as effective as prednisolone acetate administered 4 times a day for inflammatory treatment after cataract surgery." | 9.51 | Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial. ( Del Papa, M; Ferroni, C; Ferroni, V; Idiart, C; Kaufer, R; Marino, F; Masseroni, M; Nuñez, M; Passerini, MS; Valvecchia, G; Zaldívar, R, 2022) |
| "Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively." | 9.14 | Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. ( Cooke, DL; Crockett, RS; Korenfeld, MS; Silverstein, SM; Vogel, R, 2009) |
| "To compare intraocular pressure (IOP) outcomes between 2 common, commercially available corticosteroid drops: difluprednate ophthalmic emulsion 0." | 7.85 | Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. ( Ernest, P; McBain, M; Mian, SI; Musch, DC; Niziol, LM; Person, E; Tijunelis, MA, 2017) |
| "Difluprednate administered twice a day was at least as effective as prednisolone acetate administered 4 times a day for inflammatory treatment after cataract surgery." | 5.51 | Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial. ( Del Papa, M; Ferroni, C; Ferroni, V; Idiart, C; Kaufer, R; Marino, F; Masseroni, M; Nuñez, M; Passerini, MS; Valvecchia, G; Zaldívar, R, 2022) |
| "Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively." | 5.14 | Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. ( Cooke, DL; Crockett, RS; Korenfeld, MS; Silverstein, SM; Vogel, R, 2009) |
| "Patients treated with difluprednate or loteprednol had statistically similar resolution of their AC cell grade and corneal edema at 1 day, 1 week, and 1 month postoperatively (P>0." | 3.88 | Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery. ( Abessi, B; Brooksby, L; Schultze, RL, 2018) |
| "To compare intraocular pressure (IOP) outcomes between 2 common, commercially available corticosteroid drops: difluprednate ophthalmic emulsion 0." | 3.85 | Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. ( Ernest, P; McBain, M; Mian, SI; Musch, DC; Niziol, LM; Person, E; Tijunelis, MA, 2017) |
| "Randomised-controlled trials (RCTs) comparing difluprednate and prednisolone acetate regardless of the dosing regimen used." | 2.61 | Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis. ( Basiony, A; KhalafAllah, MT; Salama, A, 2019) |
| " In this regard, the present study was conducted with the aim of studying the efficacy of using fixed drug combination (Difluprednate and Moxifloxacin) in reducing ocular inflammation and pain in post-operative patients undergoing cataract surgery." | 1.46 | Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India. ( Anuradha, A; Nishath, S; Rashmi, G; Shilpa, R; Vidyadevi, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Valvecchia, G | 1 |
| Kaufer, R | 1 |
| Ferroni, C | 1 |
| Zaldívar, R | 1 |
| Masseroni, M | 1 |
| Idiart, C | 1 |
| Ferroni, V | 1 |
| Marino, F | 1 |
| Nuñez, M | 1 |
| Del Papa, M | 1 |
| Passerini, MS | 1 |
| KhalafAllah, MT | 1 |
| Basiony, A | 1 |
| Salama, A | 1 |
| Tijunelis, MA | 1 |
| Person, E | 1 |
| Niziol, LM | 1 |
| Musch, DC | 1 |
| Ernest, P | 1 |
| McBain, M | 1 |
| Mian, SI | 1 |
| Abessi, B | 1 |
| Brooksby, L | 1 |
| Schultze, RL | 1 |
| Vidyadevi, M | 1 |
| Anuradha, A | 1 |
| Rashmi, G | 1 |
| Shilpa, R | 1 |
| Nishath, S | 1 |
| Singh, A | 1 |
| Gupta, N | 1 |
| Kumar, V | 1 |
| Tandon, R | 1 |
| Wilson, ME | 1 |
| Lambert, SR | 1 |
| Plager, DA | 1 |
| VanderVeen, D | 1 |
| Roarty, J | 1 |
| O'Halloran, H | 1 |
| Kaur, S | 1 |
| Sukhija, J | 1 |
| Korenfeld, MS | 1 |
| Silverstein, SM | 1 |
| Cooke, DL | 1 |
| Vogel, R | 1 |
| Crockett, RS | 1 |
| Li, JY | 1 |
| Terry, MA | 1 |
| Goshe, J | 1 |
| Shamie, N | 1 |
| Davis-Boozer, D | 1 |
| Liu, MP | 1 |
| Hwang, FS | 1 |
| Dunn, JP | 1 |
| Stark, WJ | 1 |
| Bower, KS | 1 |
| Liu, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multi-center, Controlled, Double-blind Study to Evaluate the Efficacy and Tolerability of a Steroid/Antibiotic Associated Treatment Following Cataract Extraction by Means of Phaco-emulsification[NCT02973880] | Phase 3 | 180 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery[NCT00429923] | Phase 3 | 219 participants (Actual) | Interventional | Completed | |||
| A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery[NCT00430092] | Phase 3 | 219 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Measured on a 0 to 4 scale: 0 is ≤ 1 cell; 1 is 2-10 cells; 2 is 11-20 cells; 3 is 21-50 cells; 4 is > 50 cells." (NCT00429923)
Timeframe: Day 8 (QID)
| Intervention | participants (Number) |
|---|---|
| Proportion of subjects w/AC cell grade=0 on Day 8 | |
| Difluprednate 0.05% BID | 0 |
| Difluprednate 0.05% QID | 19 |
| Placebo | 13 |
"Measured on a 0 to 4 scale: 0 is ≤ 1 cell; 1 is 2-10 cells; 2 is 11-20 cells; 3 is 21-50 cells; 4 is > 50 cells." (NCT00430092)
Timeframe: Day 8 (QID)
| Intervention | participants (Number) |
|---|---|
| Proportion of Subjects w/AC cell grade=0 on Day 8 | |
| Difluprednate 0.05% BID | 0 |
| Difluprednate 0.05% QID | 18 |
| Placebo | 7 |
1 review available for fluprednisolone and Complication, Postoperative
| Article | Year |
|---|---|
Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis.
Topics: Animals; Anti-Inflammatory Agents; Cataract Extraction; Fluprednisolone; Humans; Postoperative Care; | 2019 |
3 trials available for fluprednisolone and Complication, Postoperative
| Article | Year |
|---|---|
Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day for cataract postsurgical inflammation treatment: noninferiority trial.
Topics: Cataract; Eye Diseases; Fluprednisolone; Humans; Inflammation; Phacoemulsification; Postoperative Co | 2022 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female | 2009 |
A prospective randomized study of medications after silicone intubation.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Drug Combinations; Female; | 1996 |
8 other studies available for fluprednisolone and Complication, Postoperative
| Article | Year |
|---|---|
Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension.
Topics: Cataract Extraction; Fluprednisolone; Glucocorticoids; Humans; Incidence; Intraocular Pressure; Ocul | 2017 |
Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
Topics: Aged; Aged, 80 and over; Anterior Chamber; Anti-Inflammatory Agents; Cataract Extraction; Cornea; Co | 2018 |
Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India.
Topics: Anti-Bacterial Agents; Cataract Extraction; Dose-Response Relationship, Drug; Drug Combinations; End | 2017 |
Toxic anterior segment syndrome following phakic posterior chamber IOL: a rarity.
Topics: Adult; Anterior Eye Segment; Diagnosis, Differential; Endophthalmitis; Female; Fluprednisolone; Gluc | 2018 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Anti-Inflammatory Agents; Cataract; Cataract Extraction; Child; Double-Blind Method; Fluprednisolone | 2017 |
Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study.
Topics: Anti-Inflammatory Agents; Cataract; Cataract Extraction; Child; Double-Blind Method; Fluprednisolone | 2017 |
Graft rejection after Descemet's stripping automated endothelial keratoplasty: graft survival and endothelial cell loss.
Topics: Aged; Cell Count; Corneal Endothelial Cell Loss; Descemet Stripping Endothelial Keratoplasty; Endoth | 2012 |
Hypopyon uveitis following LASIK in a patient with ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Astigmatism; Colitis, Ulcerative; Fluprednisolone; Gl | 2012 |